Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Free Report) have earned an average rating of “Moderate Buy” from the thirteen brokerages that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $195.08.

JAZZ has been the subject of several analyst reports. JPMorgan Chase & Co. boosted their price target on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, March 22nd. Barclays reduced their price objective on shares of Jazz Pharmaceuticals from $235.00 to $230.00 and set an “overweight” rating for the company in a research report on Friday, March 1st. HC Wainwright reduced their price objective on shares of Jazz Pharmaceuticals from $204.00 to $200.00 and set a “buy” rating for the company in a research report on Thursday, March 14th. Stifel Nicolaus boosted their price objective on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $180.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, March 22nd.

Read Our Latest Report on Jazz Pharmaceuticals

Jazz Pharmaceuticals Trading Down 1.2 %

Shares of JAZZ stock opened at $117.55 on Wednesday. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.85 and a current ratio of 2.24. The stock has a market capitalization of $7.41 billion, a P/E ratio of 19.21, a price-to-earnings-growth ratio of 1.66 and a beta of 0.59. The company has a 50 day moving average price of $122.71 and a 200 day moving average price of $124.10. Jazz Pharmaceuticals has a fifty-two week low of $111.25 and a fifty-two week high of $147.98.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.01 billion. Equities research analysts predict that Jazz Pharmaceuticals will post 16.24 EPS for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other news, CFO Philip L. Johnson acquired 12,000 shares of the business’s stock in a transaction on Friday, March 1st. The stock was bought at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the transaction, the chief financial officer now owns 27,932 shares in the company, valued at $3,342,063.80. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CAO Patricia Carr sold 1,936 shares of the company’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the transaction, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Philip L. Johnson purchased 12,000 shares of the stock in a transaction dated Friday, March 1st. The shares were bought at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the purchase, the chief financial officer now owns 27,932 shares in the company, valued at $3,342,063.80. The disclosure for this purchase can be found here. 4.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Los Angeles Capital Management LLC grew its stake in Jazz Pharmaceuticals by 558.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 322,775 shares of the specialty pharmaceutical company’s stock valued at $41,780,000 after acquiring an additional 273,764 shares during the last quarter. AQR Capital Management LLC grew its stake in Jazz Pharmaceuticals by 40.8% in the 3rd quarter. AQR Capital Management LLC now owns 179,111 shares of the specialty pharmaceutical company’s stock valued at $23,184,000 after acquiring an additional 51,871 shares during the last quarter. Thompson Siegel & Walmsley LLC grew its stake in Jazz Pharmaceuticals by 242.8% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 270,574 shares of the specialty pharmaceutical company’s stock valued at $35,023,000 after acquiring an additional 191,648 shares during the last quarter. Hudson Bay Capital Management LP acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at about $4,884,000. Finally, FMR LLC grew its stake in Jazz Pharmaceuticals by 8.1% in the 3rd quarter. FMR LLC now owns 1,333,129 shares of the specialty pharmaceutical company’s stock valued at $172,560,000 after acquiring an additional 100,349 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

(Get Free Report

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Featured Articles

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.